The role of gene therapy for craniofacial and dental tissue engineering

Advanced Drug Delivery Reviews

Volumn 58, Issue 4, 2006, Pages 577-591

  Nussenbaum, Brian ^a   Krebsbach, Paul H ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

Author keywords

Bone morphogenetic protein; Craniofacial; Gene therapy; Tissue engineering

Indexed keywords

DENTAL PROSTHESES; IMPLANTS (SURGICAL); MOLECULAR BIOLOGY; PATIENT TREATMENT; PROTEINS; TISSUE;

BONE MORPHOGENETIC PROTEIN; CRANIOFACIAL; GENE THERAPY; TISSUE ENGINEERING;

GENETIC ENGINEERING;

ADENOVIRUS VECTOR; BONE MORPHOGENETIC PROTEIN; PLASMID VECTOR; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT GROWTH FACTOR; RECOMBINANT OSTEOGENIC PROTEIN 1; RECOMBINANT PROTEIN;

BONE DEFECT; BONE GRAFT; BONE REGENERATION; BONE REMODELING; CELL BASED GENE THERAPY; CELL DIFFERENTIATION; CRANIOFACIAL MALFORMATION; CRANIOFACIAL SURGERY; DISEASE SEVERITY; GENE THERAPY; GENE TRANSFER; HEALING; HUMAN; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TOOTH MALFORMATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WOUND HEALING;

ANIMALS; BONE REGENERATION; FACIAL BONES; FACIAL INJURIES; GENE THERAPY; HUMANS; PERIODONTIUM; SKULL; TISSUE ENGINEERING; WOUNDS AND INJURIES;

EID: 33745272272     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2006.03.009     Document Type: Review

References (100)

1. Fuchs J.R., Nasseri B.A., and Vacanti J.P. Tissue engineering: a 21st century solution to surgical reconstruction. Ann. Thorac. Surg. 72 (2001) 577-591
2. Lynch S.E. Introduction. In: Lynch S.E., Genco R.J., and Marx R.E. (Eds). Tissue Engineering Applications in Maxillofacial Surgery and Periodontics (1999), Quintessence Publishing Carol Stream, Illinois xi-xii
3. Bell E. Tissue engineering in perspective. In: Lanza R.P., Langer R., and Vacanti J. (Eds). Principles of Tissue Engineering. 2nd ed. (2000), Academic Press, San Diego xxxvi
4. Minas T., and Chiu R. Autologous chondrocyte implantation. Am. J. Knee Surg. 13 (2000) 41-50
5. Boyce S.T., and Warden G.D. Principles and practices for treatment of cutaneous wounds with cultured skin substitutes. Am. J. Surg. 183 (2002) 445-456
6. Burkus J.K., Gornet M.F., Dickman C.A., et al. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J. Spinal Disord. Tech. 15 (2002) 337-349
7. Friedlaender G.E., Perry C.R., Cole J.D., et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J. Bone Jt. Surg. 83 Suppl. 1 (2001) 151-158
8. Urist M.R. Bone formation by autoinduction. Science 150 (1965) 893-899
9. Celeste A.J., Lannazzi J.A., and Taylor R.C. Identification of transforming growth factor-β superfamily members present in bone-inductive protein purified from bovine bone. Proc. Natl. Acad. Sci. 87 (1990) 9843-9847
10. Reddi A.H. Bone morphogenetic proteins: from basic science to clinical applications. J. Bone Jt. Surg. 83 Suppl. 1 (2001) 1-6
11. Nohe A., Keating E., Knaus P., and Petersen N.O. Signal transduction of bone morphogenetic protein receptors. Cell. Signal. 16 (2004) 291-299
12. Miyazawa K., Shinozaki M., Hara T., Furuya T., and Miyazono K. Two major Smad pathways in TGF-β superfamily signaling. Genes Cells 7 (2002) 1191-1204
13. Zwijsen A., Verschueren K., and Huylebroeck D. New intracellular components of bone morphogenetic protein/Smad signaling cascades. FEBS Lett. 546 (2003) 133-139
14. Balemans W., and Hul W.V. Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. Dev. Biol. 250 (2002) 231-250
15. Murakami G., Watabe T., Takaoka K., and Miyazono T. Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. Mol. Biol. Cell (2003) 2809-2817
16. Seeherman H., Li R., and Wozney J. A review of preclinical program development for evaluating injectable carriers for osteogenic factors. J. Bone Jt. Surg. 85 Suppl. 3 (2003) 96-108
17. Lieberman J.R., Daluiski A., and Einhorn T.A. The role of growth factors in the repair of bone: biology and clinical applications. J. Bone Jt. Surg. 84 (2002) 1032-1045
18. Einhorn T.A. Clinical applications of recombinant human BMPs: early experience and future development. J. Bone Jt. Surg. 85 (2003) 82-88
19. Osyczka A.M., Diefenderfer D.L., and Bhargave G. Different effects of BMP-2 on marrow stromal cells from human and rat bone. Cells Tissues Organs 176 (2004) 109-119
20. McKay B. Commercial approval of rhBMP-2 in spinal fusions: bringing the product to the market. In: Sandell L.J., and Grodzinsky A.J. (Eds). Tissue Engineering in Musculoskeletal Clinical Practice (2004), American Academy of Orthopedic Surgeons, Rosemeont 61-72
21. Seeherman H. The influence of delivery vehicles and their properties on the repair of segmental defects and fractures with osteogenic factors. J. Bone Jt. Surg. 83 Suppl. 1 (2001) 79-81
22. Muschler G.F., Nitto H., Boehm C.A., and Easley K.A. Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. J. Orthop. Res. 19 (2001) 117-125
23. Giannoudis P.V., and Tziopis C. Clinical applications of BMP-7. The UK perspective. Injury 36S (2005) S47-S50
24. Luhmann S.J., Bridwell K.H., Cheng I., et al. Use of bone morphogenetic protein-2 for adult spinal deformity. Spine 30 (2005) S110-S117
25. Schliephake H. Bone growth factors in maxillofacial skeletal reconstruction. Int. J. Oral Maxillofac. Surg. 31 (2002) 469-484
26. Gafni Y., Turgeman G., and Liebergal M. Stem cells as vehicles for orthopedic gene therapy. Gene Ther. 11 (2004) 417-426
27. Korbling M., Estrov Z., and Champlin R. Adult stem cells and tissue repair. Bone Marrow Transplant. 32 (2003) S23-S24
28. Sylvester K.G., and Longaker M.T. Stem cells: review and update. Arch. Surg. 139 (2004) 93-99
29. Jiang Y., Jahagirdar B.N., and Reinhardt R.L. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418 (2002) 41-49
30. Cao B., and Huard J. Muscle-derived stem cells. Cell Cycle 3 (2004) 104-107
31. Gimble J., and Guilak F. Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. Cytotherapy 5 (2003) 362-369
32. Bruder S.P., Fink D.J., and Caplan A.I. Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J. Cell. Biochem. 56 (1994) 283-294
33. Rutherford R.B., Maolli M., Franceschi R.T., et al. Bone morphogenetic protein-transduced human fibroblasts convert to osteoblasts and form bone in vivo. Tissue Eng. 8 (2002) 441-452
34. Hannallah D., Peterson B., Lieberman J.R., et al. Gene therapy in orthopedic surgery. J. Bone Jt. Surg. 84 (2002) 1046-1061
35. Fang J., Zhu Y., Smiley E., et al. Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Proc. Natl. Acad. Sci. 93 (1996) 5753-5758
36. Peng H., Wright V., and Usas A. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J. Clin. Invest. 110 (2002) 751-759
37. Minimide A., Boden S.D., Viggeswarapu M., et al. Mechanism of bone formation with gene transfer of the cDNA encoding for the Intracellular protein LMP-1. J. Bone Jt. Surg. 85 (2003) 1030-1039
38. Partridge K.A., and Oreffo R.O. Gene delivery in bone tissue engineering: progress and prospects using viral and non-viral strategies. Tissue Eng. 10 (2004) 295-307
39. Lou J. Bone engineering with mesenchymal stem cells and gene therapy. In: Sandell L.J., and Grodzinsky A.J. (Eds). Tissue Engineering in Musculoskeletal Clinical Practice (2004), American Academy of Orthopedic Surgeons, Rosemeont 123-130
40. Maddox Schek R., Hollister S.J., and Krebsbach P.H. Delivery and protection of adenoviruses using biocompatible hydrogels for localized gene therapy. Molec. Ther. 9 (2004) 130-138
41. Gansbacher B. European Society of Gene Therapy: Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position of the European Society of Gene Therapy (ESGT). J. Gene Med. 5 (2003) 261-262
42. Krebsbach P.H., Mankani M.H., Satomura K., Kuznetsov S.A., and Robey P.G. Repair of craniotomy defects using bone marrow stromal cells. Transplantation 66 (1998) 1272-1278
43. Shang Q., Wang Z., and Liu W. Tissue-engineered bone repair of sheep cranial defects with autologous bone marrow stromal cells. J. Craniofac. Surg. 12 (2001) 586-593
44. Bruder S.P., Kraus K.H., Goldberg V.M., and Kadiyala S. The effect of implants loaded with autologous mesenchymal stem cells on the healing of canine segmental bone defects. J. Bone Jt. Surg. 80 (1998) 985-996
45. Quarto R., Mastrogiacomo M., and Cancedda R. Repair of large bone defects with the use of autologous bone marrow stromal cells. New Engl. J. Med. 344 (2001) 385-386
46. Gang C., Yan Z., Wei L., et al. Clinical application of tissue engineered bone repair of human craniomaxillofacial bone defects. Natl. Med. J. China 83 (2003) 1676-1681
47. Vacanti C.A., Bonassar L.J., Vacanti M.P., et al. Replacement of an avulsed phalanx with tissue-engineered bone. N. Engl. J. Med. 344 (2001) 1511-1514
48. Sato K., and Urist M.R. Induced regeneration of calvaria by bone morphogenetic protein (BMP) in dogs. Clin. Orthop. Relat. Res. 197 (1985) 301-311
49. Toriumi D.M., Katler H.S., and Luxemberg D.P. Mandibular reconstruction with a recombinant bone-inducing factor. Arch. Otolaryngol., Head Neck Surg. 117 (1991) 1101-1112
50. Boyne P.J., Nakamura A., and Shabahang S. Evaluation of the long-term effect of function on rhBMP-2 regenerated hemimandibulectomy defects. Br. J. Oral Maxillofac. Surg. 37 (1999) 344-352
51. Marukawa E., Asahina L., Oda M., et al. Functional reconstruction of the nonhuman primate mandible using recombinant human bone morphogenetic protein-2. Int. J. Oral Maxillofac. Surg. 31 (2002) 287-295
52. Sheehan J.P., Sheehan J.M., Seeherman H., Quigg M., and Helm G.A. The safety and utility of recombinant human bone morphogenetic protein-2 for cranial procedures in a nonhuman primate model. J. Neurosurg. 98 (2003) 125-130
53. Chang S.C.N., Chuang H.L., and Chen Y.R. Ex vivo gene therapy in autologous bone marrow stromal stem cells for tissue-engineered maxillofacial bone regeneration. Gene Ther. 10 (2003) 2013-2019
54. Park J., Ries J., Gelse K., et al. Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes. Gene Ther. 10 (2003) 1089-1098
55. Adamo A.K., and Szal R.L. Timing, results, and complications of mandibular reconstructive surgery: report of 32 cases. J. Oral Surg. 37 (1979) 755-763
56. Lawson W., and Biller H.F. Mandibular reconstruction: bone graft techniques. Otolaryngol.-Head Neck Surg. 90 (1982) 589-594
57. Urken M.L., Bridger A.G., Zur K.B., et al. The scapular osteofasciocutaneous flap: a 12 year experience. Arch. Otolaryngol., Head Neck Surg. 127 (2001) 862-869
58. Urken M.L., Buchbinder D., Costantino P.D., et al. Oromandibular reconstruction using microvascular composite flaps: report of 210 cases. Arch. Otolaryngol., Head Neck Surg. 124 (1998) 46-55
59. Hartman E.H., Spauwen P.H., and Jansen J.A. Donor-site complications in vascularized bone flap surgery. J. Invest. Surg. 15 (2002) 185-197
60. Rogers S.N., Lakshmiah S.R., Narayan B., et al. A comparison of the long-term morbidity following deep circumflex iliac and fibula free flaps for reconstruction following head and neck cancer. Plast. Reconstr. Surg. 112 (2003) 1517-1525
61. Parker V.T., and Urbaniak J.R. Donor-site morbidity with use of vascularized autogenous fibular grafts. J. Bone Jt. Surg. 78 (1996) 204-211
62. Chin M., Ng T., Tom W.K., and Carstens M. Repair of alveolar clefts with recombinant human bone morphogenetic protein (rhBMP-2) in patients with clefts. J. Craniofac. Surg. 16 (2005) 778-789
63. Warnke P.H., and Coren A.J. First experiences with recombinant human bone morphogenetic protein 7 (osteogenic protein 1) in a human case in maxillofacial surgery. Plast. Reconstr. Surg. 111 (2003) 2471-2472
64. Moghadam H.G., Urist M.R., Sandor G.K.B., et al. Successful mandibular reconstruction using a BMP bioimplant. J. Craniofac. Surg. 12 (2001) 119-127
65. Wurzler K.K., DeWeese T.L., Sebald W., et al. Radiation-induced impairment of bone healing can be overcome by recombinant human bone morphogenetic protein-2. J. Craniofac. Surg. 9 (1998) 131-137
66. Lorente C.A., Song B.Z., and Donoff R.B. Healing of bone defects in the irradiated and unirradiated rat mandible. J. Oral Maxillofac. Surg. 50 (1992) 1305-1309
67. Khouri R.K., Brown D.M., Koudsi B., et al. Repair of calvarial defects with flap tissue: role of bone morphogenetic proteins and competent responding tissues. Plast. Reconstr. Surg. 98 (1996) 103-109
68. Okubo Y., Bessho K., Fujimura K., et al. Preclinical study of recombinant human bone morphogenetic protein-2: application of hyperbaric oxygen during bone formation under unfavourable condition. Int. J. Oral Maxillofac. Surg. 32 (2003) 313-317
69. Chen X., Kidder L.S., and Lew W.D. Osteogenic protein-1 induced bone formation in an infected segmental defect in the rat femur. J. Orthop. Res. 20 (2002) 142-150
70. Warnke P.H., Springer I.N.G., Wiltfang J., et al. Growth and transplantation of a custom vascularized bone graft in a man. Lancet 364 (2004) 766-770
71. Lindsey W.H. Osseous tissue engineering with gene therapy for facial bone reconstruction. Laryngoscope 111 (2001) 1128-1136
72. Krebsbach P.H., Gu K., Franceschi R.T., and Rutherford R.B. Gene therapy-directed osteogenesis: BMP-7-transduced human fibroblasts form bone in vivo. Hum. Gene Ther. 11 (2000) 1201-1210
73. Lee J.Y., Peng H., Usas A., et al. Enhancement of bone healing based on ex vivo gene therapy using human muscle-derived cells expressing bone morphogenetic protein 2. Hum. Gene Ther. 13 (2002) 1201-1211
74. Nussenbaum B., Rutherford R.B., and Krebsbach P.H. Bone regeneration in cranial defects previously treated with radiation. Laryngoscope 115 (2005) 1170-1177
75. Nussenbaum B., Rutherford R.B., and Teknos T.N. Ex vivo gene therapy for skeletal regeneration in cranial defects compromised by postoperative radiotherapy. Hum. Gene Ther. 14 (2003) 1107-1115
76. Forrest C.R., O'Donovan D.A., Yeung I., et al. Efficacy of radioprotection in the prevention of radiation-induced craniofacial bone growth inhibition. Plast. Reconstr. Surg. 109 (2002) 1311-1323
77. Horiuchi H., Saito N., Kinoshita T., et al. Enhancement of recombinant human bone morphogenetic protein-2 (rhBMP-2)-induced new bone formation by concurrent treatment with parathyroid hormone and a phosphodiesterase inhibitor, pentoxifylline. J. Bone Miner. Metab. 22 (2004) 329-334
78. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J. Clin. Oncol. 18 (2000) 3339-3345
79. Hensley M.L., Schuchter L.M., Lindley C., et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J. Clin. Oncol. 17 (1999) 3333-3355
80. Costantino P.D., Friedman C.D., and Steinberg M.J. Irradiated bone and its management. Otolaryngol. Clin. North Am. 28 (1995) 1021-1037
81. Marx R.E. Osteoradionecrosis: a new concept of its pathophysiology. J. Oral Maxillofac. Surg. 41 (1983) 283-288
82. Gerber H.P., Vu T.H., Ryan A.M., et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5 (1999) 623-628
83. Zelzer E., Mamluk R., Ferrara N., Johnson R.S., and Schipani E. VEGFA is necessary for chondrocyte survival during bone development. Development 131 (2004) 2161-2171
84. Takita H., Kikuchi M., Sato Y., and Kuboki Y. Inhibition of BMP-induced ectopic bone formation by an antiangiogenic agent (epigallocatechin 3-gallate). Connect. Tissue Res. 43 (2002) 520-523
85. Smith B.D., Smith G.L., Carter D., et al. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinomas. J. Clin. Oncol. 18 (2000) 2046-2052
86. Teknos T.N., Cox C., Yoo S., et al. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck 24 (2002) 1004-1011
87. Baum B.J., Kok M., Tran S.D., and Yamano S. The impact of gene therapy on dentistry: a revisiting after six years. J. Am. Dent. Assoc. 133 1 (2002) 35-44
88. Jin Q., Anusaksathien O., Webb S.A., Printz M.A., and Giannobile W.V. Engineering of tooth-supporting structures by delivery of PDGF gene therapy vectors. Molec. Ther. 9 4 (2004) 519-526
89. Dunn C.A., Jin Q., Taba Jr. M., Franceschi R.T., Bruce Rutherford R., and Giannobile W.V. BMP gene delivery for alveolar bone engineering at dental implant defects. Molec. Ther. 11 2 (2005) 294-299
90. Nakashima M., Iohara K., Ishikawa M., Ito M., Tomokiyo A., Tanaka T., and Akamine A. Stimulation of reparative dentin formation by ex vivo gene therapy using dental pulp stem cells electrotransfected with growth/differentiation factor 11 (Gdf11). Hum. Gene Ther. 15 11 (2004) 1045-1053
91. Rutherford R.B. BMP-7 gene transfer to inflamed ferret dental pulps. Eur. J. Oral Sci. 109 6 (2001) 422-424
92. Zufferey R., and Aebischer P. Salivary glands and gene therapy: the mouth waters. Gene Ther. 11 19 (2004) 1425-1426
93. Baum B.J., Wellner R.B., and Zheng C. Gene transfer to salivary glands. Int. Rev. Cyt. 213 (2002) 93-146
94. Baum B.J., Zheng C., Cotrim A.P., Goldsmith C.M., Atkinson J.C., Brahim J.S., Chiorini J.A., Voutetakis A., Leakan R.A., Van Waes C., Mitchell J.B., Delporte C., Wang S., Kaminsky S.M., and Illei G.G. Transfer of the AQP1 cDNA for the correction of radiation-induced salivary hypofunction. Biochim. Biophys. Acta (2005) (electronic publication ahead of print)
95. Shan Z., Li J., Zheng C., Liu X., Fan Z., Zhang C., Goldsmith C.M., Wellner R.B., Baum B.J., and Wang S. Increased fluid secretion after adenoviral-mediated transfer of the human aquaporin-1 cDNA to irradiated miniature pig parotid glands. Molec. Ther. 11 3 (2005) 444-451
96. Delporte C., O'Connell B.C., He X., Lancaster H.E., O'Connell A.C., Agre P., and Baum B.J. Increased fluid secretion after adenoviral-mediated transfer of the aquaporin-1 cDNA to irradiated rat salivary glands. Proc. Natl. Acad. Sci. U. S. A. 94 7 (1997) 3268-3273
97. Voutetakis A., Bossis I., Kok M.R., Zhang W., Wang J., Cotrim A.P., Zheng C., Chiorini J.A., Nieman L.K., and Baum B.J. Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders. J. Endocrinol. 185 3 (2005) 363-372
98. Kok M.R., Baum B.J., Tak P.P., and Pillemer S.R. Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjogren's syndrome. Ann. Rheum. Dis. 62 11 (2003) 1038-1046
99. Tucker S.N., Lin K., Stevens S., Scollay R., Bennett M.J., and Olson D.C. Salivary gland genetic vaccination: a scalable technology for promoting distal mucosal immunity and heightened systemic immune responses. Vaccine 22 19 (2004) 2500-2504
100. Tucker S.N., Lin K., Stevens S., Scollay R., Bennett M.J., and Olson D.C. Systemic and mucosal antibody responses following retroductal gene transfer to the salivary gland. Molec. Ther. 8 3 (2003) 392-399